Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running

Ranked 3rd among pharmaceutical companies for sustainable leadership

Recognized for environmental sustainability, equitable pricing strategies in low- and middle-income countries, and senior executive female representation

News provided by
Takeda Pharmaceutical Company Limited Tokyo Stock Exchange 4502
Jan. 22, 2020 11:35
OSAKA, JAPAN--(Business Wire / Korea Newswire)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive year. Corporate Knights assesses more than 7,300 companies against 21 key performance indicators. It uses these indicators to determine the top 1% most sustainable companies in the world, which are announced annually at the World Economic Forum in Davos, Switzerland.

“Building sustainable value is a fundamental part of the way we do business at Takeda, and we are proud to be recognized as a global leader in sustainability,” said Christophe Weber, President and CEO. “This recognition by Corporate Knights is a testament to the strong foundation Takeda has laid and the progress we have already achieved. We remain steadfast in our commitment to realizing Better Health and a Brighter Future for all.”

Corporate Knights highlighted Takeda’s performance in the following areas:

· Significant year-on-year improvement in energy, water and greenhouse gas productivity scores.
· High marks for clean revenue, which measures revenue earned by providing access to medicine for top priority diseases in low- and middle-income countries through equitable pricing strategies.
· Three times the average score for female representation among senior executives.

In addition to the Global 100 index, Takeda is recognized by many other environmental, social and governance (ESG) investment valuations. As a long-standing member of the United Nations Global Compact, Takeda’s sustainability efforts are guided by key international targets, such as the Sustainable Development Goals (SDGs).

(To view the table, please visit https://bwnews.pr/2v6ZYzy)

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit www.takeda.com

About Takeda’s Sustainable Value Report

Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005554/en/

Website: https://www.takeda.com/

View Korean version of this release

Contact

Takeda Pharmaceutical Company Limited
Japanese Media
Kazumi Kobayashi
+81 (0) 3-3278-2095
Kazumi.Kobayashi@Takeda.com

Media outside of Japan
Katie Joyce
+1-617-678-9370
Katie.Joyce@Takeda.com